UniQure NV (NASDAQ: QURE) experienced a steep decline in its stock price, tumbling about 36% after the U.S. Food and Drug Administration informed the company that data from its early- to mid-stage AMT-130 trial would not be sufficient to support a marketing application.
The FDA reached this determination in final minutes from a meeting held on January 30, which UniQure received. The agency stated that the study results, when compared to an external control, cannot serve as the primary evidence of effectiveness that is required for approval.
AMT-130 is a gene therapy candidate intended to treat Huntington’s disease, a rare neurodegenerative disorder that impairs motor function. The therapy is administered directly into the brain through the insertion of a micro-catheter.
Analysts on the sell side reacted to the agency's conclusion and the market response.
Leerink analysts said they were not surprised to see a roughly 40% premarket drop, noting that this outcome represented the worst-case scenario for many investors.
Stifel analysts described the news as disappointing but added that it was not entirely unexpected, referencing a recent, high-profile interview given by FDA Commissioner Dr. Makary that they characterized as unorthodox. Stifel noted that UniQure expects to convene a Type B meeting with the FDA in the second quarter to discuss study designs. They emphasized that a sham-controlled study requirement would introduce meaningful risk and raised the broader question of whether UniQure has alternative avenues to engage the agency.
Truist analysts framed the FDA recommendation as inconsistent with guidance given to other companies developing central nervous system gene therapies. They pointed to an example in which the FDA agreed to a single-arm open-label study of NGN-401 for Rett syndrome. Truist acknowledged differences in delivery routes - NGN-401 is administered via the intracerebroventricular route while AMT-130 uses an intraparenchymal approach - but noted both procedures involve burr holes, which the FDA commented are associated with morbidity. Given the devastating nature of Huntington’s disease, Truist argued the risk/benefit calculation favors AMT-130.
UniQure has indicated it plans to hold a Type B meeting with the FDA in the second quarter to discuss potential study designs and next steps. The company and analysts are now evaluating options in light of the FDA's position that the existing data, compared against an external control, cannot serve as primary approval evidence.
Key context and implications remain centered on regulatory strategy for AMT-130, potential trial redesigns, and near-term market volatility for UniQure shares as stakeholders await further engagement between the company and the FDA.